Pluristyx Announces Patent Allowance of Next Generation Synthetic mRNA Technology in Japan, Solidifying Global iPSC Reprogramming Leadership

Pluristyx, a leading provider of advanced induced pluripotent stem cell (iPSC) technologies and proprietary, genetically engineered solutions, today announced the Japanese Patent Office (JPO) issued a ...
News Medical

New directions in cell therapy: iPSC platforms and in vivo reprogramming

Induced pluripotent stem cells (iPSCs) are derived from adult cells, such as skin or blood cells, which have been “reprogrammed” back to a stem-cell-like state. This transformation grants them the ...
The Scientist

New iPSC Reprogramming Method Uses Proteins Instead of DNA

Researchers have attained the holy grail of cellular reprogramming: inducing pluripotency without using any DNA-based materials. Using only a cocktail of purified proteins and a chemical additive, ...
Drug Target Review

Why scaling human-derived models is pharma’s next big challenge

Many drugs still fail after promising preclinical results, raising difficult questions about how disease is modelled in the ...
Business Wire

Cellistic® Announces Successful Certification of its GMP Facility Dedicated to iPSC-Based Off-the-shelf Cell Therapy Manufacturing Solutions

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Cellistic®, a pioneer in iPSC-based off-the-shelf cell therapy development and manufacturing, announces the successful audit and GMP certification of its ...
Business Wire

Revolutionary Elephant iPSC Milestone Reached in Colossal’s Woolly Mammoth Project

Colossal scientists achieve global first; technology promises seminal advancements for engineering Woolly Mammoth phenotypes in in vitro cellular models, developmental biology, and attaining balance ...